About Surmodics, Inc.
https://www.surmodics.comSurmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).
CEO
Gary R. Maharaj
Compensation Summary
(Year 2020)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-12-07 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 5
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:1.17M
Value:$50.32M
BLACKROCK, INC.
Shares:1.15M
Value:$49.37M
BLACKROCK FUND ADVISORS
Shares:1.07M
Value:$45.81M
Summary
Showing Top 3 of 184
About Surmodics, Inc.
https://www.surmodics.comSurmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $29.57M ▲ | $26.23M ▲ | $-5.32M ▼ | -17.99% ▲ | $-0.37 ▼ | $-5.24M ▼ |
| Q2-2025 | $28.09M ▼ | $24.27M ▼ | $-5.21M ▼ | -18.55% ▼ | $-0.36 ▼ | $-4.01M ▼ |
| Q1-2025 | $29.92M ▼ | $24.98M ▼ | $-3.65M ▼ | -12.2% ▼ | $-0.26 ▼ | $21K ▼ |
| Q4-2024 | $33.23M ▲ | $25.17M ▼ | $-3.45M ▲ | -10.38% ▲ | $-0.24 ▲ | $1M ▲ |
| Q3-2024 | $30.34M | $26.39M | $-7.55M | -24.9% | $-0.53 | $-2.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $32.73M ▲ | $169.82M ▲ | $58.51M ▲ | $111.31M ▲ |
| Q2-2025 | $31.15M ▲ | $163.21M ▼ | $52.97M ▲ | $110.25M ▼ |
| Q1-2025 | $30.14M ▼ | $163.74M ▼ | $51.97M ▼ | $111.77M ▼ |
| Q4-2024 | $40.11M ▲ | $178.56M ▲ | $59.66M ▲ | $118.9M ▲ |
| Q3-2024 | $38.17M | $177.41M | $59.27M | $118.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.32M ▼ | $1.41M ▲ | $-4.93M ▼ | $-29K ▼ | $-2.9M ▼ | $904K ▲ |
| Q2-2025 | $-5.21M ▼ | $949K ▲ | $-2.28M ▼ | $48K ▲ | $-962K ▲ | $630K ▲ |
| Q1-2025 | $-3.65M ▼ | $-7.89M ▼ | $3.7M ▼ | $-1.2M ▲ | $-5.97M ▼ | $-8.2M ▼ |
| Q4-2024 | $-3.45M ▲ | $3.66M ▲ | $9.46M ▲ | $-1.56M ▼ | $11.81M ▲ | $3.12M ▲ |
| Q3-2024 | $-7.55M | $-2.03M | $-6.72M | $66K | $-8.73M | $-2.99M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Product | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ | $20.00M ▲ |
 Research Development And Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Gary R. Maharaj
Compensation Summary
(Year 2020)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-12-07 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 5
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:1.17M
Value:$50.32M
BLACKROCK, INC.
Shares:1.15M
Value:$49.37M
BLACKROCK FUND ADVISORS
Shares:1.07M
Value:$45.81M
Summary
Showing Top 3 of 184